RXRX logo

RXRXRecursion Pharmaceuticals Inc

$3.26
$0.11
(3.49%)
Today
Updated: 11:29 AM EDT
EarningsAug 5
Mkt Cap$1.67B
Vol5.94M
News
all
press releases
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.06, moving 5.12% from the previous trading session.
Zacks
News Placeholder
More News
News Placeholder
Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Recursion Pharmaceuticals vs. Schrodinger: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsRecursion Pharmaceuticals uses its AI-driven platform to manage a deep pipeline of drug candidates through strategic partnerships with industry giants...
Nasdaq News: Markets
News Placeholder
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now?
Key PointsRecursion Pharmaceuticals is using AI to improve how we develop drugs...
Nasdaq News: Markets
News Placeholder
Recursion Pharmaceuticals (RXRX) Hits 52-Week Low; Is It In Oversold Territory?
Recursion Pharmaceuticals (RXRX) Hits 52-Week Low; Is It In Oversold Territory...
Yahoo! Finance: News
News Placeholder
Recursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy Now
Recursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy Now...
Yahoo! Finance: News
News Placeholder
Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back
Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.read more...
Benzinga
News Placeholder
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
Recursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year.
Zacks
News Placeholder
Recursion Pharmaceuticals Q1 Earnings Call Highlights
Recursion Pharmaceuticals (NASDAQ:RXRX) leadership used its latest earnings call to emphasize a sharper focus on translating artificial intelligence-enabled discovery into clinical and partnership "proof points," while maintaining what it described as tighter financial discipline. CEO and President...
MarketBeat
News Placeholder
Recursion Pharmaceuticals (NASDAQ:RXRX) Issues Quarterly Earnings Results
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.